Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hematologic Malignancies
•
Medical Oncology
•
Myeloma
•
NCI-CCC Tumor Board Question
•
Mayo Clinic
•
NCI-CCC Myeloma Tumor Board Question
•
Mayo
•
Multiple Myeloma
After the MAJESTEC-3 results and once approved, what is your approach to choosing between Tec-Dara vs. cilta-cel versus another triplet for Multiple Myeloma in first relapse
Related Questions
What is your management approach for CAR-T induced motor neurologic deficits (cyclophosphamide/IVIG/steroids, etc.) and any prophylactic approach to an early, rapid rise in absolute lymphocyte count post CAR-T infusion?
If you are using talquetamab as bridging before BCMA CAR-T therapy, when do you assess for response and/or stop the talquetamab?
For a patient with a metastatic solid tumor in remission on a checkpoint inhibitor who also has R/R multiple myeloma, would you feel comfortable with a bispecific T-cell engager antibody?
Would you offer live vaccines (e.g., MMRV/measles) to patients on bispecific antibodies for multiple myeloma?
How would you manage a patient w/ blastoid variant MCL given data w/ all the current BTKi regimens TRIANGLE, BOVEN, and TRAVERSE
Under what circumstances is it okay to initiate treatment for suspected multiple myeloma without a bone marrow biopsy?
Should you consider thromboprophylaxis, even for low-dose lenalidomide maintenance, post-autologous transplantation?
What are your top takeaways in Hematologic Malignancies from ASH 2024?
In light of data from TRIANGLE, ECHO, and ENRICH, what is the best strategy to treat newly diagnosed patients with the blastoid variant MCL?
What is your preferred dose and schedule for maintenance drugs post autoHCT for newly diagnosed multiple myeloma?
